Diabetic Macular Edema

Despite recommendations to consult with ophthalmologists prior to initiating semaglutide, the cardiometabolic drug was not found to be linked to worsened DR outcomes.

The post hoc analysis of the phase 3 YOSEMITE/RHINE trials may support the therapeutic role of dual Ang-2/VEGF-A inhibition with faricimab for DME.

Rishi P. Singh, MD, and Michael A. Klufas, MD, provide an overview of the significance of and need for biosimilars in the ophthalmology space, and review the approval pathway for biosimilars.

A post hoc analysis of the phase 3 YOSEMITE and RHINE trials found significantly more patients had leakage resolution with faricmab than with aflibercept at Week 16.

Results from the phase 3 YOSEMITE and RHINE trials show more than half of faricimab treat-and-extend patients met the criteria for a potential every-20-week dosing extension.

Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.

The risk of diabetic retinopathy appears considerably lower in SGLT2 inhibitor users than in DPP4 inhibitor users among patients with type 2 diabetes.

SGLT2 inhibitors added to metformin were associated with a significantly higher risk of diabetic retinopathy progression in the short term but significantly lower risk in the long term.

Moritz Pettenkofer, MD, presents a case of a 75-year-old male patient with nARMD who has had 53 injections of anti-VEGF therapy over 4 years.

Moritz Pettenkofer, MD, discusses the mechanisms of faricimab and presents a case study of a 66-year-old female with nARMD

Steven D. Schwartz, MD, reviews challenges and unmet needs in treatment of patients with neovascular AMD and DME.

Nondiabetic and diabetic patients without retinopathy experience similar results after treatment with an intravitreal dexamethasone implant for pseudophakic macular edema.

Switching to intravitreal dexamethasone improves visual outcomes, but does not significantly change subfoveal choroidal thickness or the choroidal vascularity index.

Mark Barakat, MD, reviews the best practices for patient communication and shared decision making.

Matthew Cunningham, MD, FASRS, provides the highlights of the YOSEMITE and RHINE trials for patients with diabetic macular edema (DME).

Mark Barakat, MD, discusses the phase 3 TENAYA and LUCERNE trials for patients with neovascular age-related macular degeneration (nAMD).

Diana Do, MD, provides an overview of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Artificial intelligence use is growing across medicine. From imaging to chatbots, ophthalmology is the center of one of these transformations.

For DME eyes that did not sufficiently respond to prior treatment, the intravitreal implant was associated with improvements in both visual and anatomic outcomes.

Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.

The association between antibiotic exposure and increased odds of AMD persisted after adjustment for well-established risk factors for the disease.

Rates of visual acuity loss among patients with neovascular age-related macular degeneration did not vary significantly in pre‐versus post‐lockdown time periods.

Factors including a longer diabetes duration and lower eGFR were associated with suboptimal treatment response to aflibercept in patients with DME.

Faricimab shows improved visual and anatomic outcomes in eyes with nAMD previously treated with aflibercept or brolucizumab.

New phase 2 study findings link levosulpiride treatment for 8 weeks with improved visual and structural outcomes and no significant adverse side effects.